<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04961307</url>
  </required_header>
  <id_info>
    <org_study_id>Cardiac safety study</org_study_id>
    <nct_id>NCT04961307</nct_id>
  </id_info>
  <brief_title>Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab</brief_title>
  <official_title>Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      By dynamically observing the changes of echocardiogram and biomarkers in breast cancer&#xD;
      patients using trastuzumab, evaluate the effect of trastuzumab on cardiac function; determine&#xD;
      the sensitivity of echocardiography and biomarker indicators And specificity, explore&#xD;
      effective and specific early warning indicators, and provide technical support for the&#xD;
      evaluation of the cardiac safety of anti-tumor drugs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thirty female breast cancer patients using trastuzumab, collected demographic and clinical&#xD;
      information of all patients before chemotherapy, performed echocardiography (conventional&#xD;
      echocardiography, three-dimensional spot tracking technology), and collected blood samples to&#xD;
      detect plasma biology Markers (TnT, BNP, GDF-15, topoisomerase), follow-up echocardiography&#xD;
      and biomarkers at 1 month, 3 months and 6 months after chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time ending</measure>
    <time_frame>6 months</time_frame>
    <description>180 days after chemotherapy</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cardiotoxicity</condition>
  <condition>Antitumor Drugs</condition>
  <condition>Breast Cancer</condition>
  <condition>Trastuzumab</condition>
  <arm_group>
    <arm_group_label>Women with breast cancer using trastuzumab</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>30 female breast cancer patients using trastuzumab, collected demographic and clinical information of all patients before chemotherapy, performed echocardiography (conventional echocardiography, three-dimensional spot tracking technology), and collected blood samples to detect plasma biology Markers (TnT, BNP, GDF-15, topoisomerase</description>
    <arm_group_label>Women with breast cancer using trastuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        30 female breast cancer patients using trastuzumab, collected demographic and clinical&#xD;
        information of all patients before chemotherapy, performed echocardiography (conventional&#xD;
        echocardiography, three-dimensional spot tracking technology), and collected blood samples&#xD;
        to detect plasma biology Markers (TnT, BNP, GDF-15, topoisomerase)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with breast cancer (18-70 years old)&#xD;
&#xD;
          -  Patients who are planning to undergo trastuzumab for the first time&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Organic heart disease such as coronary heart disease, heart valve disease,&#xD;
             cardiomyopathy&#xD;
&#xD;
          -  liver and kidney failure&#xD;
&#xD;
          -  severe cerebrovascular disease&#xD;
&#xD;
          -  chronic obstructive pulmonary disease&#xD;
&#xD;
          -  rheumatic immune system disease&#xD;
&#xD;
          -  other tumors&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Peking</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weixian T Xu</last_name>
      <phone>13810695447</phone>
      <email>xwxbird05@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Xin Liu</last_name>
      <phone>18801362704</phone>
      <email>liuxinlucile2019@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>July 4, 2021</last_update_submitted>
  <last_update_submitted_qc>July 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac safety</keyword>
  <keyword>Antitumor drugs</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Trastuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

